FDA Approves First OTC Glucose Monitor for Kids Gets Green Light

The FDA has cleared Dexcom’s (NASDAQ: DXCM) Stelo Glucose Biosensor System as the first over‑the‑counter continuous glucose monitor (CGM) that children can use, extending earlier OTC use in adults to kids as young as 2 who do not use insulin. This makes Stelo the first CGM that families can buy for children without a prescription, for tracking glucose patterns rather than making insulin‑dosing decisions.

How the Stelo Sensor Works

Stelo is a small sensor worn on the back of the upper arm that continuously measures glucose in the fluid under the skin and transmits readings to a smartphone app. Each sensor lasts up to 15 days before it needs to be replaced, giving users a rolling view of their glucose trends rather than single point‑in‑time fingerstick readings.

Who Stelo Is Designed For

Stelo is aimed at:

• Children and adults with diabetes managed without insulin (for example, on oral medications) who want to better understand their glucose patterns.
• People without diabetes who want to see how food, exercise, sleep, and other lifestyle factors affect their glucose levels over time.

It is not intended for people who use insulin, those with frequent severe low blood sugars, or people on dialysis, because it does not provide real‑time urgent alerts or support insulin‑dosing decisions. Children should use it with adult caregiver supervision.

What This Means for Families

For families, Stelo offers an easier way to monitor a child’s glucose patterns without fingersticks or a prescription. It can help caregivers see how specific foods, activities, illness, or routines influence a child’s glucose, and use those insights to adjust habits and have more informed conversations with healthcare providers.

Investor Angle

From an investor perspective, this decision opens a new OTC pediatric segment for CGMs, expanding beyond the traditional base of insulin‑using patients and into a much larger pool of non‑insulin users and health‑conscious consumers. It strengthens Dexcom’s position in consumer‑oriented metabolic tracking, potentially supporting higher sensor volumes, more diversified revenue, and deeper brand recognition as glucose monitoring moves further into the mainstream wellness space.